Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis by Tichet, Mélanie et al.
Tumour-derived SPARC drives vascular permeability
and extravasation through endothelial VCAM1
signalling to promote metastasis
Me´lanie Tichet, Virginie Prod ’Homme, Nina Fenouille, Damien Ambrosetti,
Aude Mallavialle, Michael Cerezo, Mickae¨l Ohanna, Ste´phane Audebert,
Ste´phane Rocchi, Damien Giacchero, et al.
To cite this version:
Me´lanie Tichet, Virginie Prod ’Homme, Nina Fenouille, Damien Ambrosetti, Aude Mallavialle,
et al.. Tumour-derived SPARC drives vascular permeability and extravasation through en-
dothelial VCAM1 signalling to promote metastasis. Nature Communications, Nature Publish-
ing Group, 2015, 6, pp.6993. <10.1038/ncomms7993>. <hal-01295443>
HAL Id: hal-01295443
https://hal.archives-ouvertes.fr/hal-01295443
Submitted on 11 Apr 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
1  
Tumour-derived	SPARC	drives	vascular	permeability	and	extravasation	through	endothelial	VCAM1	
signalling	to	promote	metastasis.	
Mélanie	 Tichet1,2,	 Virginie	 Prod’Homme1,2,	 Nina	 Fenouille1,2,	 Damien	 Ambrosetti2,3,	 Aude	
Mallavialle1,2,	Michael	Cerezo2,4,	Mickaël	Ohanna2,4,	Stéphane	Audebert5,	Stéphane	Rocchi2,4,	Damien	
Giacchero2,6,	Fériel	Boukari1,2,6,	Maryline	Allegra2,4,	Jean-Claude	Chambard2,7,	Jean-Philippe	Lacour2,6,	
Jean-François	Michiels2,3,	Jean-Paul	Borg5,	Marcel	Deckert1,2,	and	Sophie	Tartare-Deckert1,2
1INSERM,	U1065,	Microenvironnement,	Signalisation	et	Cancer.	Centre	Méditerranéen	de	Médecine	
Moléculaire	(C3M),	151	Route	de	Saint-Antoine	de	Ginestière,	BP	23194,	06204	Nice	Cedex	3,	France.	
2Université	de	Nice	Sophia	Antipolis,	Faculté	de	Médecine,	06107	Nice,	France.	
3Centre	 Hospitalier	 Universitaire	 (CHU)	 de	 Nice,	 Hôpital	 Pasteur,	 Laboratoire	 Central	 d'Anatomo	
Pathologie,	06002	Nice,	France.	
4INSERM,	 U1065,	 Biologie	 et	 Pathologies	 des	 Mélanocytes,	 C3M,	 151	 Route	 de	 Saint-Antoine	 de	
Ginestière,	BP	23194,	06204	Nice	Cedex	3,	France.	
5CRCM,	 INSERM	U1068,	 Institut	Paoli-Calmettes,	Aix-Marseille	Université,	UM105;	CNRS	UMR7258,	
Bp	30059,	13273	Marseille	Cedex	9,	France.	
6CHU	de	Nice,	Hôpital	Archet	2,	Service	de	Dermatologie,	06202	Nice,	France.	
7INSERM,	 U1091,	 CNRS,	 UMR	 7277,	 iBV,	 Faculté	 des	 Sciences,	 Parc	 Valrose,	 06108	 Nice	 Cedex	 2,	
France.		
Correspondence	and	requests	materials	should	be	addressed	to	S.T.-D.	(email:	tartare@unice.fr).
2  
	
Abstract	
Disruption	of	 the	endothelial	barrier	by	 tumour-derived	 secreted	 factors	 is	 a	 critical	 step	 in	 cancer	
cell	 extravasation	 and	 metastasis.	 Here,	 by	 comparative	 proteomic	 analysis	 of	 melanoma	
secretomes,	 we	 identify	 the	 matricellular	 protein	 SPARC	 as	 a	 novel	 tumour-derived	 vascular	
permeability	factor.	SPARC	deficiency	abrogates	tumour-initiated	permeability	of	lung	capillaries	and	
prevents	 extravasation,	 whereas	 SPARC	 overexpression	 enhances	 vascular	 leakiness,	 extravasation	
and	 lung	 metastasis.	 SPARC-induced	 paracellular	 permeability	 is	 dependent	 on	 the	 endothelial	
VCAM1	receptor	and	p38	MAPK	signalling.	Blocking	VCAM1	impedes	melanoma-induced	endothelial	
permeability	and	extravasation.	The	clinical	relevance	of	our	findings	is	highlighted	by	high	levels	of	
SPARC	detected	in	tumour	from	human	pulmonary	melanoma	lesions.	Our	study	establishes	tumour-
produced	 SPARC	 and	 VCAM1	 as	 regulators	 of	 cancer	 extravasation,	 revealing	 a	 novel	 targetable	
interaction	for	prevention	of	metastasis.	
	
	
	
	
	
	 	
3  
	
Metastasis	is	a	challenging	clinical	problem	and	the	primary	cause	of	death	from	cancer.	
Tumour	 progression	 towards	metastasis	 occurs	 by	 a	 complex	multi-step	 process	 whereby	 tumour	
cells	dissociate	from	their	primary	site	of	growth,	invade	surrounding	tissues,	intravasate	into	a	blood	
vessel,	survive	in	circulation,	adhere	to	and	extravasate	from	the	vessel,	and	form	a	new	tumour	at	
secondary	 site.	 The	metastatic	 behaviour	 of	 cancer	 cells	 relies	 on	 both	 cell-autonomous	 and	 non-
autonomous	processes,	the	latter	involving	dynamic	interactions	with	non–malignant	cells	within	the	
tumour	microenvironment1-3.	
Cutaneous	melanoma	 is	 notorious	 for	 its	 proclivity	 for	 early	 and	 extensive	metastatic	 spread	 and	
recognized	 as	 one	 of	 the	most	 virulent	 and	 resistant	 to	 therapy	 of	 human	 cancers.	 In	most	 cases	
melanoma	 derives	 from	 an	 epidermal	melanocyte	 and	 progresses	 into	 a	 primary	 tumour	 that	 can	
invade	 into	 the	dermis	and	draining	 lymph	nodes	and	 from	there	disseminate	 to	distant	organs4,	 5.	
Early	 stage	 melanomas	 can	 be	 successfully	 treated	 by	 surgical	 resection.	 However,	 patients	 with	
more	 advanced	 forms	 of	 melanomas	 have	 a	 much	 lower	 chance	 of	 long-term	 survival.	 Recent	
progresses	 in	 melanoma	 treatments	 have	 led	 to	 improved	 survival	 in	 patients	 with	 metastatic	
disease6,	7.	However,	the	prognosis	remains	still	very	poor	for	most	patients.	Thus,	studies	aiming	at	
defining	 the	 driver	 mechanisms	 of	 metastatic	 dissemination	 could	 lead	 to	 novel	 therapeutic	
strategies	that	could	improve	clinical	outcomes	for	melanoma	patients.		
The	mechanisms	that	mediate	haematogenous	metastatic	 formation	depend,	 in	part,	on	the	ability	
of	 circulating	 tumour	 cells	 to	 exit	 the	 bloodstream	 through	 the	 blood	 vessel	 wall	 composed	 of	
endothelial	cells,	the	basement	membrane,	and	perivascular	cells,	and	enter	the	tissue	parenchyma.	
The	opening	of	endothelial	 junctions	is	the	prelude	for	the	transmigration	process	 in	which	tumour	
cells	can	move	through	the	junctions	between	adjacent	endothelial	cells	thereby	enabling	metastatic	
seeding	 in	 the	 invaded	organs8.	 This	process	 is	 related	 to	 the	well-studied	physiological	process	of	
paracellular	 diapedesis	 of	 leukocytes	 during	 inflammation	 and	 requires	 disruption	 of	 the	 barrier	
function	of	 the	endothelium9.	The	paracellular	permeability	of	 the	endothelium	 is	 regulated	by	the	
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dynamic	 opening	 and	 closure	 of	 intercellular	 junctions.	 Transmembrane	 adhesion	 proteins	 are	
located	at	both	adherens	and	tight	junctions	and	function	to	connect	adjacent	endothelial	cells	and	
to	 sustain	 the	 barrier	 integrity10.	 The	 stability	 of	 these	 contacts	 is	 maintained	 by	 coordinated	
mechanisms	based	on	contractile	forces	produced	by	the	acto-myosin	complex	and	interaction	of	the	
actin	 cytoskeleton	 with	 adherens	 or	 tight	 junctions-associated	 proteins	 including	 ß-catenin,	 α-
catenin,	zona	occludens	1	(ZO1)	and	2	(ZO2),	and	others10,	11.	The	vascular	endothelial	cadherin	(VE-
cadherin)	 represents	 one	 of	 the	 major	 adhesion	 systems	 that	 support	 the	 endothelial	 barrier	
function.	Signalling	pathways	 that	 increase	vascular	permeability	generally	affect	adhesive	 function	
of	VE-cadherin	 in	part	 through	 tyrosine	phosphorylation	of	 constituents	of	 adherens	 junctions	and	
activation	 of	 acto-myosin	 contractibility	 accompanied	 by	 reorganization	 of	 the	 actin	 cytoskeleton	
that	cause	formation	of	stress	fibers	and	intercellular	gaps8,	12.		
Vascular	 permeability	 is	 thus	 a	 complex	 phenomenon	 involving	 coordinated	 regulation	 of	 diverse	
signalling	 pathways	 in	 the	 endothelial	 cell.	 Within	 the	 malignant	 melanoma	 microenvironment,	
communication	 between	 tumour	 cells,	 their	 secreted	 factors	 and	 the	 endothelium	 is	 thought	 to	
increase	paracellular	vascular	permeability.	Thus,	disruption	of	endothelium	integrity	by	tumour	cells	
appears	as	a	critical	and	early	event	that	 facilitates	extravasation,	yet	 the	way	by	which	metastatic	
melanoma	cells	affect	vascular	permeability	is	not	fully	understood.	
Here,	we	 have	 investigated	 the	 secreted	 factors	 and	 paracrine	 signalling	 pathways	 responsible	 for	
tumour-initiated	vascular	permeability	during	cancer	cell	extravasation	 in	the	context	of	melanoma	
metastasis.	We	 identify	 the	matricellular	 SPARC	protein,	 as	 a	 critical	 tumour-secreted	permeability	
factor	 and	 a	 novel	 paracrine	 mediator	 of	 endothelium	 permeability	 during	 melanoma	 metastatic	
dissemination	to	lungs.	Abnormal	expression	of	SPARC	has	been	reported	in	various	cancer	cell	types	
including	 melanoma13,	 in	 which	 SPARC	 was	 shown	 to	 play	 a	 key	 role	 in	 melanoma	 cell	
tumorigenicity14-16.	However,	 its	 role	 as	 a	 paracrine	mediator	of	 haematogenous	metastasis	 during	
extravasation	 remains	 unclear.	We	 report	 here	 the	 first	 evidence	 that	 tumour	 cell-derived	 SPARC	
instigates	the	disruption	of	the	endothelial	barrier	through	binding	to	vascular	cell	adhesion	molecule	
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1	(VCAM1)	and	activation	of	p38	MAPK-mediated	signalling	pathways	 leading	to	actin	cytoskeleton	
reorganization	 and	 opening	 of	 endothelial	 intercellular	 junctions.	 Our	 study	 brings	 new	 and	
important	insights	into	the	mechanisms	of	tumour	cell	extravasation	at	the	endothelial	barrier	during	
melanoma	metastasis.	
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Results	
Metastatic	 melanoma	 releases	 vascular	 permeability	 factors.	 We	 reasoned	 that	 malignant	
melanoma	cells	produce	secreted	permeability	factors	and	use	paracrine	signalling	to	communicate	
with	the	endothelial	barrier	in	order	to	extravasate	during	metastatic	dissemination.	To	address	this	
issue	we	prepared	conditioned	medium	(CM)	from	normal	human	melanocytes	(NHM)	and	a	panel	of	
melanoma	cells	displaying	different	metastatic	potential	(Fig.	1a)	to	analyse	how	these	CM	modulate	
endothelial	permeability.	Endothelial	cell	monolayer	permeability	has	been	evaluated	in	vitro	using	a	
FITC-Dextran	Transwell	assay	(Supplementary	Fig.	1a).	Primary	Human	umbilical	vein	endothelial	cells	
(HUVECs)	 grown	 to	 confluence	were	 exposed	 to	 normal	 growth	medium	 or	 to	 CM	 prepared	 from	
NHM	 or	 melanoma	 cell	 lines	 (1205Lu,	 A375,	 SKMel28	 and	 501Mel).	 501Mel	 cells	 were	 chosen	
because	compared	to	the	other	melanoma	cells	used	they	show	no	metastatic	potential	in	mice.	We	
also	analysed	the	effect	of	CM	derived	from	short-term	cultures	of	metastatic	melanoma	cells	(Pt1,	
Pt2	 and	 Pt3).	 As	 shown	 in	 Supplementary	 Fig.	 1a,	monolayer	 permeability	was	 significantly	 higher	
following	 exposure	 to	CM	 collected	 from	1205Lu,	A375	 and	 SKMel28	 cell	 lines	 or	 from	 short-term	
cultures	 compared	 with	 CM	 collected	 from	 NHM.	 In	 contrast,	 CM	 derived	 from	 non-metastatic	
501Mel	cells	did	not	greatly	 increase	endothelial	permeability	when	compared	 to	 the	effect	of	CM	
prepared	 from	 the	 other	 melanoma	 cells.	 These	 results	 indicate	 that	 metastatic	 melanoma	 cell-
derived	CM	contains	factors	that	are	sufficient	to	promote	junctional	permeability.			
	
Tumour-derived	SPARC	induces	vascular	permeability	 in	vitro.	In	order	to	identify	the	extracellular	
factors	acting	on	endothelial	permeability,	we	performed	a	comparative	mass	spectrometry	analysis	
of	 serum-free	 CM	prepared	 from	metastatic	 1205Lu	 cells	 versus	 non-metastatic	 501Mel	 cells.	 This	
analysis	 revealed	 that	metastatic	 cells	 released	 in	 the	 extracellular	milieu	 a	 pattern	of	 functionally	
diverse	 proteins	 that	was	 qualitatively	 and	 quantitatively	 different	 as	 compared	 to	 non-metastatic	
cells	 (Supplementary	Table	1).	Notably,	several	proteins	 involved	 in	ECM	organization	(TENA,	SPRC,	
MMP2,	 TICN1,	 TIMP2,	 CSPG2),	 adhesion	 (FINC,	 LAMB1,	 TSP1/2,	 ITB1,	 L1CAM,	 CD44,	 ITAV,	 ITB3),	
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migration	and	 inflammation	(IL6,	GROA,	 IL8,	TNR1,	CCL2),	and	TGFß	signalling	(LTBP3,	TGFB1)	were	
dramatically	 enriched	 in	 CM	 from	 metastatic	 1205Lu	 cells,	 whereas	 proteins	 associated	 with	 a	
melanocytic	profil	(PEDF)17,	K2C8	and	K2C1818,	or	skin	function	(CHLE)19,	were	more	abundant	in	CM	
from	non-metastatic	501Mel	cells	(Supplementary	Fig.	1b).	Other	proteins	differentially	expressed	in	
1205Lu	CM	vs	 501Mel	 included	 factors	 involved	 in	additional	 important	 tumour	 cell	 functionalities	
such	 as	 angiogenesis	 (NRP1),	 fibrinolysis	 (PAI1,	 GDN,	 UPAR),	 or	 associated	 with	 extracellular	
microvesicles	and	exosomes	(HS90B,	RAB7A).		
The	discovery	that	SPARC,	a	matricellular	protein	involved	in	tumour	cell	invasion	and	survival20,	and	
endothelial	 barrier	 function21,	 was	 10	 fold	 more	 abundant	 in	 metastatic	 melanoma	 cell	 CM	 as	
compared	 to	 CM	 from	 a	 poorly	 metastatic	 cell	 prompted	 us	 to	 investigate	 whether	 SPARC	
contributes	 to	 paracrine	 induction	 of	 vascular	 permeability	 by	 melanoma	 cell-derived	 CM.	 We	
therefore	 engaged	 different	 approaches	 to	 manipulate	 SPARC	 expression	 and	 function.	 First,	
knockdown	of	 SPARC	 expression	 using	 siRNA	 strongly	 attenuated	 the	 abilities	 of	 CM	derived	 from	
1205Lu,	 A375	 and	 SKMel28	 melanoma	 cell	 lines	 or	 from	 a	 short-term	 culture	 to	 promote	 FITC-
Dextran	 permeability	 across	 HUVECs	 monolayers	 (Fig.	 1b).	 Inhibition	 of	 melanoma	 CM-induced	
vascular	 permeability	 after	 SPARC	 knockdown	 was	 also	 evident	 when	 FITC-Dextran	 assays	 were	
performed	across	primary	human	pulmonary	microvascular	endothelial	 cells	 (HPMECs)	monolayers	
(Fig.	1c).	Using	a	complementary	approach,	we	showed	that	immunodepletion	of	SPARC	protein	from	
melanoma-derived	CM	impaired	its	capacity	to	increase	endothelial	monolayer	permeability	(Fig.	1d).	
Conversely,	501Mel	cells	engineered	to	overexpress	myc-tagged	SPARC	protein	(cl.SPARC)	produced	
CM	with	higher	potential	for	increasing	FITC-Dextran	permeability	as	compared	to	CM	from	parental	
cells	(Fig.	1b).	In	order	to	test	whether	the	reduced	capacity	to	promote	endothelial	permeability	was	
a	direct	consequence	of	the	absence	of	SPARC	in	CM,	SPARC-silenced	CM	was	rescued	by	increasing	
doses	of	exogenous	SPARC.		As	shown	in	Fig.	1e,	a	recombinant	tumour	source	of	SPARC	was	able	to	
rescue	 dampened	 endothelial	 permeability	 induced	 by	 SPARC-silenced	 CM	 in	 a	 dose-dependent	
manner.	 Examination	 of	 SPARC	 secretion	 by	 melanoma	 cells	 using	 ELISA	 analyses	 confirmed	 that	
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metastatic	melanoma	cells	produced	significantly	higher	levels	of	SPARC	than	501Mel	cells	or	normal	
melanocytes	 (Supplementary	 Fig.	 1c).	 Given	 the	 emerging	 role	 of	 tumour-derived	 extracellular	
vesicles	 like	 exosomes	 in	 paracrine	 signalling	 and	 endothelial	 function	 during	 metastasis22,	 we	
verified	that	SPARC	is	released	as	a	soluble	factor	in	melanoma	culture	supernatants	of	1205Lu	cells.	
Depletion	of	exosomal-like	particles	from	culture	supernatants	by	ultracentrifugation	indicated	that	
enhanced	endothelial	permeability	 function	of	melanoma	CM	was	maximally	mediated	by	 tumour-
derived	soluble	factors.	This	experiment	also	demonstrated	the	non-vesicular	origin	of	SPARC	in	the	
CM	 from	 1205Lu	 cells	 (Supplementary	 Fig.	 1d).	 Of	 note,	 no	 significant	 effect	 of	 cell	 density	 was	
observed	in	the	regulation	of	SPARC	secretion	by	1205Lu	melanoma	cells	(Supplementary	Fig.	2).		
The	effect	of	secreted	SPARC	on	endothelial	monolayer	integrity	was	next	examined	by	fluorescence	
microscopy.	HUVECs	cells	were	allowed	to	grow	to	form	tight	monolayers	on	culture	plates.	At	this	
point,	monolayers	were	 exposed	 to	medium	 conditioned	 by	 1205Lu	 cells	 transfected	with	 control	
siRNA	 (siCTRL)	 or	 SPARC	 siRNA	 (siSPARC).	 Staining	 with	 antibodies	 against	 the	 tight	 junction	
component	 ZO1	 or	 the	 adherens	 junction	 component	 ß-catenin	 revealed	 that	 the	 monolayer	
integrity	 was	 dramatically	 perturbed	 by	 addition	 of	 CM	 from	 control	 1205Lu	 cells	 (Fig.	 1f	 and	
Supplementary	 Fig.	 3a).	 Staining	 of	 the	 actin	 cytoskeleton	 with	 phalloidin	 produced	 similar	
observations.	 In	 contrast,	 SPARC-depleted	 CM	 displayed	 severely	 impaired	 capacity	 to	 disrupt	 the	
endothelial	barrier	and	to	open	intercellular	gaps.	The	formation	of	intercellular	gaps	was	quantified	
(Fig.	1g)	and	changes	were	found	significant.	When	examined	on	monolayers	of	 lung	microvascular	
cells	HPMECs,	a	similar	disrupting	activity	of	SPARC	was	observed.	The	opening	of	intercellular	gaps	
in	endothelial	monolayers	was	a	direct	effect	of	 SPARC	as	demonstrated	by	 rescue	experiments	 in	
which	 exogenous	 SPARC	 restored	 the	 ability	 of	 SPARC-depleted	 CM	 to	 alter	 endothelial	 integrity	
(Supplementary	Fig.	3b,c).		
We	also	examined	the	functional	contribution	of	SPARC	in	the	induction	of	vascular	permeability	 in	
malignant	 glioma	 cells,	 which	 also	 rely	 on	 its	 expression	 for	 invasive	 behaviour23,	 24.	 Importantly,	
SPARC-silenced	CM	collected	from	the	glioma	cell	 line	U87	transfected	with	SPARC	siRNA	exhibited	
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disabled	 potential	 for	 increasing	 endothelial	 cell	 permeability	 (Supplementary	 Fig.	 4).	 Collectively,	
these	findings	support	a	role	for	SPARC	in	tumour	cell-induced	disruption	of	endothelial	monolayer	
integrity	in	vitro.		
	
Tumour-derived	SPARC	alters	pulmonary	permeability	 in	mice.	We	proceeded	 further	 to	examine	
the	 involvement	 of	 SPARC	 in	melanoma	 cell-induced	 hyperpermeability	 of	 lung	 capillaries	 in	 vivo.	
Control	or	SPARC	siRNA-treated	1205Lu	melanoma	cells	were	injected	into	nude	mice.	One-day	post	
inoculation,	FITC-Dextran	was	injected	into	circulation,	in	order	to	measure	vessel	permeability.	After	
thirty	minutes,	 the	 accumulation	of	 the	 high	molecular	weight	 tracer	 in	 the	 lung	parenchyma	was	
analysed	by	 fluorescence	microscopy	 (Fig.	2a,b).	No	FITC	signal	was	present	 in	 the	 lungs	 that	were	
not	 inoculated	 with	 tumour	 cells	 (data	 not	 shown).	 However,	 FITC-Dextran	 was	 detected	 at	
significant	levels	within	lungs	from	mice	inoculated	with	SPARC-competent	cells	as	evidenced	by	the	
diffuse	 areas	 of	 fluorescence	 signal	 observed	 in	 lung	 sections.	 In	 contrast,	 the	 intensity	 of	
fluorescence	was	 significantly	abolished	by	SPARC	silencing	 (Fig.	2c).	Permeable	Dextran	exudation	
was	quantified	in	the	lysates	of	individual	lungs.	These	analyses	confirmed	that	compared	to	control	
cells,	 vascular	 permeability	 was	 dramatically	 reduced	 in	 lungs	 from	 mice	 inoculated	 with	 SPARC-
deficient	tumour	cells,	indicating	that	knockdown	of	SPARC	prevents	tumour-induced	permeability	of	
lung	 capillaries	 (Fig.	 2d).	 By	 contrast,	 501Mel	 cells	 overexpressing	 SPARC	 showed	 a	 significant	
increased	 in	 the	 amount	 of	 FITC-Dextran	 lodged	 in	 the	 lungs	 compared	 to	 parental	 cells	 (Fig.	 2e).	
These	 results	 indicate	 that	SPARC	expressed	by	melanoma	cells	 can	disrupt	 the	barrier	 integrity	of	
lung	capillaries.	
	
SPARC	 promotes	 tumour	 cell	 extravasation	 and	 lung	 metastasis.	 Increasing	 vascular	 leakiness	
properties	in	the	lung	is	an	early	event	in	tumour	cell	extravasation	and	metastatic	colonization.	We	
therefore	 investigated	whether	 the	regulation	of	vascular	permeability	by	tumour	SPARC	facilitates	
the	 passage	 of	 melanoma	 cells	 across	 the	 endothelial	 barrier	 and	 the	 colonization	 of	 lungs	 by	
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metastatic	cells.	First,	we	examined	the	contribution	of	SPARC	in	the	interaction	of	tumour	cells	with	
the	blood	vessel	endothelium,	a	key	process	for	transendothelial	migration	during	extravasation.	We	
attempted	 to	 mimic	 this	 in	 vitro	 by	 accessing	 melanoma	 cell	 adhesion	 on	 a	 confluent	 layer	 of	
endothelial	cells.	We	found	that	knockdown	or	overexpression	of	SPARC	did	not	significantly	affect	
melanoma	cell	adhesion	to	the	endothelial	monolayer,	indicating	that	melanoma-derived	SPARC	was	
dispensable	 for	 tumour-endothelial	 cell	 adhesion	 (Supplementary	 Fig.	 5).	We	 then	 assessed	 the	
effects	of	SPARC	knockdown	in	transendothelial	migration	of	melanoma	cell	lines	(1205Lu,	and	A375)	
and	short-term	cultured	melanoma	cells.	When	assayed	on	monolayers	of	TNFα-activated	HUVECs,	
control	 siRNA-transfected	 melanoma	 cells	 exhibited	 approximately	 2-	 to	 3-fold	 higher	 rates	 of	
migration	as	compared	with	their	SPARC-silenced	counterparts,	thereby	establishing	a	strong	positive	
link	between	SPARC	production	by	melanoma	cells	and	their	ability	to	cross	endothelial	barriers	(Fig.	
3a).	 SPARC-silenced	1205Lu	melanoma	cells	 also	displayed	a	 reduced	potential	 to	migrate	 through	
monolayers	of	HPMECs	(Fig.	3b).	The	effect	of	SPARC	depletion	in	cancer	cell	transmigration	was	also	
evidenced	in	A375	cells	stably	expressing	an	inducible	SPARC	shRNA,	and	in	three	others	melanoma	
cell	lines	(Supplementary	Fig.	6)	and	in	U87	glioma	cells	(Supplementary	Fig.	7).	In	contrast,	501Mel	
cells	 overexpressing	 SPARC	 exhibited	 an	 enhanced	 capacity	 to	 transmigrate	 across	 HUVECs	
monolayers	 (Fig.	 3c).	 Silencing	 of	 SPARC	 in	 HUVECs	 monolayers	 had	 no	 significant	 impact	 in	
melanoma	transmigration	(Supplementary	Fig.	8),	suggesting	that	migration	of	melanoma	cell	across	
endothelial	monolayers	did	not	require	the	presence	of	endothelial-derived	SPARC.		
Using	a	short-term	lung	colonization	assay	to	monitor	cancer	cell	extravasation	 in	vivo	 (Fig.	3d),	we	
evaluated	 whether	 SPARC	 levels	 affect	 extravasation	 of	 tumour	 cells	 into	 lungs.	 To	 this	 end,	
melanoma	cells	manipulated	 to	express	either	 low	or	high	 levels	of	 SPARC	were	 labelled	with	 two	
fluorescent	dyes,	mixed	 in	equal	proportions	and	 injected	 into	 the	tail	veins	of	mice.	After	30	min,	
similar	numbers	of	each	coinjected	cell	population	had	lodged	lungs	of	the	recipient	mice.	Whereas	
most	 SPARC-depleted	 1205Lu	 cells	 had	 disappeared	 from	 the	 lungs	 after	 24	 h,	 enforced	 SPARC	
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expression	 in	 501Mel	 cells	 dramatically	 increased	 their	 abilities	 to	 extravasate	 into	 the	 pulmonary	
parenchyma	(Fig.	3e,f).		
We	 next	 examined	 the	 involvement	 of	 SPARC	 in	 long-term	 lung	 colonization	 using	 bioluminescent	
melanoma	cells.	Control	and	SPARC	siRNA	1205Lu	transfectants	were	 injected	 into	the	tail	veins	of	
mice.	 Bioluminescence	 imaging	 (BLI)	 immediately	 post-injection	 confirmed	 that	 cells	 arrested	 into	
the	 lungs.	 In	 vivo	 and	 ex-vivo	 BLI	 at	 the	 assay	 endpoint	 revealed	 a	 dramatic	 reduction	 in	 lung	
colonization	by	SPARC	knockdown	cells	compared	with	control	(Fig.	4a,b).	Quantification	revealed	an	
apparent	50-fold	reduction	in	experimental	lung	metastasis	by	SPARC	knockdown	cells.	By	contrast,	
overexpression	 of	 myc-tagged	 SPARC	 in	 501Mel	 cells	 significantly	 increased	 nearly	 20-fold	 lung	
metastasis	 (Fig.	 4c).	 Immunofluorescence	 analysis	 of	 the	 expression	 of	 myc-tagged	 SPARC	 in	 lung	
sections	showed	that	individual	metastatic	lesions	retained	SPARC	expression	at	the	endpoint	of	the	
experiment	(Fig.	4d).	These	data	suggest	that	SPARC	expression	 is	sufficient	to	endow	501Mel	cells	
with	metastatic	competence	to	lungs.		
We	recently	reported	that	elevated	expression	of	SPARC	favours	melanoma	survival	and	growth	by	
inhibiting	p53	tumour	suppression	function16.	It	is	therefore	important	to	exclude	the	possibility	that	
the	observed	decrease	in	the	efficiency	of	colonization	by	SPARC-silenced	cells	was	due	to	activation	
of	p53-mediated	apoptosis.	We	therefore	used	p53	siRNA	to	prevent	death	of	SPARC-depleted	cells.	
We	knocked-down	p53	along	with	SPARC	in	1205Lu	cells	and	analysed	metastatic	foci	formation	18	
days	 post-inoculation	 into	 the	 tail	 veins	 of	 mice.	 As	 shown	 in	 Fig.	 4e,	 p53	 silencing	 did	 not	
significantly	affect	the	dramatic	reduction	of	lung	colonization	of	SPARC-depleted	cells.		
	
SPARC	 triggers	 vascular	 permeability	 via	 endothelial	 VCAM1.	 VCAM1	 has	 been	 identified	 as	 an	
endothelial	 receptor	 for	 leukocyte-derived	 SPARC25.	We	 therefore	 examined	whether	 the	 effect	 of	
tumour-derived	 SPARC	 on	 disruption	 of	 endothelial	 integrity	 and	 extravasation	 involves	 VCAM1	
signalling.	 Addition	 of	 VCAM1	 blocking	 antibodies	 to	 HUVECs	 monolayers	 dramatically	 impaired	
1205Lu	 cell	 transmigration	 abilities	 compared	 to	 control	 antibodies	 (Fig.	 5a).	 Importantly,	 the	
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presence	of	VCAM1	blocking	antibodies	abrogated	the	enhanced	effect	of	SPARC	on	transmigration	
of	501Mel	cells.	Blockade	of	VCAM1	also	prevented	endothelial	permeability	elicited	by	melanoma	
cell	 CM	 as	 assessed	 by	 FITC-Dextran	 method	 (Fig.	 5b).	 We	 also	 examined	 the	 effect	 of	 VCAM-1	
knockdown	in	endothelial	cells.	Transfection	of	siRNA	targeting	VCAM1	resulted	in	almost	complete	
reduction	of	VCAM1	protein	levels	in	both	resting	and	TNFα-activated	HUVECs	(Fig.	5c).	Knockdown	
of	VCAM1	in	activated	endothelial	cells	reduced	the	opening	of	intercellular	gaps	induced	by	1205Lu-
derived	CM	and	transmigration	(Fig.	5c,d).	Importantly,	administration	of	VCAM1	blocking	antibodies	
prior	 to	1205Lu	melanoma	cells	 inoculation	 in	mice	 significantly	blocked	 the	development	of	 early	
lung	metastatic	colonization	(Fig.	5e).	
To	further	explore	the	contribution	of	VCAM1	in	tumour-derived	SPARC’s	effect,	we	studied	the	role	
played	by	the	COOH-terminal	extracellular	Ca2+	binding	(EC)	module	of	SPARC,	a	domain	previously	
shown	implicated	in	binding	to	endothelial	cells26	and	to	VCAM125.	501Mel	cells	were	infected	with	
an	adenovirus	control	or	expressing	SPARC	or	SPARC	deleted	of	the	EC	domain,	and	transmigration	
experiments	and	FITC-Dextran	assays	were	performed.	Whereas	SPARC	enhanced	transmigration	and	
endothelial	 permeability	 capacities	 of	 501Mel	 cells,	 the	 EC	 domain-deleted	mutant	was	 unable	 to	
promote	 these	effects	 (Fig.	5f).	This	 strongly	 suggests	 that	 the	SPARC	EC	domain	 is	 responsible	 for	
mediating	 endothelial	 paracrine	 signalling	 leading	 to	 vascular	 leakage	 and	 tumour	 cell	
transmigration.	 Consistently,	 ablation	 of	 VCAM1	 abrogated	 SPARC-stimulated	 paracellular	
permeability,	indicating	that	SPARC	likely	requires	VCAM1	to	induce	alteration	in	endothelial	barrier	
integrity	(Fig.	5g).		
Leukocyte	 engagement	 of	 VCAM1	 on	 endothelial	 cells	 elicits	 multiple	 signalling	 pathways	 that	
participate	to	vascular	function	including	paracellular	permeability	27,	28.	We	therefore	examined	the	
impact	 of	 tumour-derived	 SPARC	 on	 endothelial	 cell	 signalling.	 When	 HUVECs	 monolayers	 were	
incubated	with	SPARC-containing	CM	from	1205Lu	cells	or	A375	cells,	activating	phosphorylation	of	
SRC,	 p38	MAPK	 and	myosin	 light	 chain	 2	 (MLC2)	were	 detected	 in	 endothelial	 cells.	 Compared	 to	
resting	 cells,	 TNFα-treated	 HUVECs	 exhibited	 augmented	 levels	 of	 p38	 and	MLC2	 phosphorylation	
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(Fig.	 6a	 and	 Supplementary	 Fig.	 9a-c).	 Importantly,	 these	 events	 were	 nearly	 abolished	 upon	
incubation	 of	 endothelial	 cells	 with	 CM	 depleted	 for	 SPARC	 by	 siRNA	 or	 immunoprecipitation.	 Of	
note,	exposure	of	melanoma	CM	to	endothelial	cells	did	not	modulate	activation	of	ERK,	 JNK,	AKT,	
JAK/STAT	or	FAK	signalling	pathways	(Supplementary	Fig.	9d	and	not	shown).	We	next	confirmed	the	
p38	MAPK	dependence	using	pharmacological	 inhibition.	 In	HUVECs	 treated	with	 the	p38	 inhibitor	
SB202190,	 no	 phosphorylation	 of	 the	 transcription	 factor	 ATF2	 and	MLC2	was	 observed	 following	
addition	 of	 1205Lu	 CM	 (Fig.	 6b).	 Note	 that	 SB202190	 did	 not	 inhibit	 the	 1205Lu	 CM-induced	
phosphorylation	of	 the	upstream	p38	activators,	MKK3	and	MKK6.	The	 functional	 relevance	of	 the	
p38	 signalling	 pathway	 during	 SPARC-induced	 vascular	 permeability	 was	 evidenced	 by	microscopy	
experiments	 showing	 that	 tumour	 CM-induced	 junctional	 disruption,	 F-actin	 increase	 and	
paracellular	 pores	 formation	were	 prevented	 by	 SB202190	 (Fig.	 6c).	 Finally,	 inhibition	 of	 p38	 also	
impaired	transmigration	of	1205Lu	cells	and	CM-induced	vascular	permeability	to	FITC-Dextran	(Fig.	
6d,e).	 Together,	 these	 experiments	 demonstrate	 that	 interaction	 of	 tumour-secreted	 SPARC	 with	
endothelial	 VCAM1	 triggers	 p38	 MAPK	 signalling	 towards	 vascular	 endothelium	 permeability	 and	
melanoma	extravasation.		
	As	 VCAM1	 has	 been	 shown	 to	 mediate	 endothelial	 junction	 disruption	 through	 Rac-dependent	
production	of	reactive	oxygen	species	(ROS)	and	activation	of	p38	during	leukocyte	transmigration29,	
ROS	levels	were	monitored	in	endothelial	cells	exposed	to	CM	prepared	from	1205Lu	melanoma	cells	
(Supplementary	 Fig.	 9e,f).	 An	 increase	 in	 ROS	 production	 upon	 exposure	 of	 CM	 was	 observed	
compared	 to	 control	medium.	Moreover,	we	 found	 that	 preincubation	with	 the	 oxygen	 scavenger	
NAC	prevented	melanoma	cell	CM-induced	activating	phosphorylation	of	p38	and	MLC2,	providing	
evidence	 that	p38	activation	occurs	downstream	of	ROS.	 These	 findings	point	 to	a	 role	 for	ROS	as	
signalling	molecules	involved	in	melanoma	cell-induced	p38	MAPK	pathway	leading	to	gap	formation	
and	endothelial	permeability.		
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SPARC	 level	 is	 associated	 with	 human	 metastatic	 melanoma.	 Despite	 earlier	 studies	 that	 have	
correlated	 levels	 of	 SPARC	 to	 the	 early	 stages	 of	 malignant	 melanomas	 and	 found	 expression	 of	
SPARC	associated	with	invasion	and	poor	clinical	income	30-32,	no	evidence	has	been	provided	for	an	
association	of	SPARC	with	distant	melanoma	metastases.	To	determine	the	clinical	relevance	of	our	
findings,	we	 investigated	 SPARC	 expression	 in	 human	melanoma	 lung	metastases	 and	 amounts	 of	
circulating	 SPARC	 in	 blood	 from	 patients	 with	 stage	 4	 metastatic	 disease.	 SPARC	 level	 in	 lung	
metastasis	samples	 from	patients	with	metastatic	melanoma	(MM)	was	analysed	by	 IHC.	 In	 four	of	
four	 samples	 evaluated,	 a	 strong	 SPARC	 immunoreactivity	 was	 detected	 in	 association	 with	
metastatic	melanoma	cells.	Strikingly,	no	expression	of	SPARC	was	 found	 in	non-tumoral	stroma	of	
lung	tissues	(Fig.	7a).	Regarding	the	high	expression	of	SPARC	found	 in	melanoma	lung	metastases,	
we	 thus	 sought	evidence	 for	 a	potential	 link	between	SPARC	expression	and	advanced	melanoma.	
We	measured	 the	SPARC	 level	 in	 serum	 from	nine	MM	patients	and	eight	healthy	volunteers,	 and	
found	a	statistically	significant	increase	of	SPARC	in	clinical	samples	(1.01	±	0.28	µg/ml)	versus	control	
individuals	 (0.67	 ±	 0.17	 µg/ml)	 (Fig.	 7b).	 Human	 SPARC	 circulating	 levels	 were	 also	 detected	 in	
melanoma-xenografted	 mice	 bearing	 lung	 metastases	 in	 comparison	 with	 tumour-free	 mice	
(Supplementary	 Fig.	 10).	 Results	 with	 clinical	 samples	 are	 in	 agreement	 with	 our	 functional	
observations	 pointing	 to	 a	 critical	 role	 of	 SPARC	 during	 paracrine	 remodelling	 of	 the	 vascular	
endothelium	by	circulating	cancer	cells.	In	addition,	our	results	identified	VCAM1	as	a	central	ligand	
for	 tumour-derived	 SPARC	 during	 malignant	 endothelium	 disruption	 and	 melanoma	 cell	
extravasation	in	lungs.	Our	mechanistic	findings	are	summarized	in	the	schematic	(Fig.	7c).	
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Discussion	
Metastasis	 arises	 via	 a	 complex	 succession	 of	 events,	which	 involves	 dissemination	 and	 growth	 of	
cancer	 cells	 to	 distant	 organs.	 Many	 of	 these	 complex	 events	 are	 orchestrated	 by	 molecular	
pathways	operating	within	 the	malignant	cells,	and	by	 interactions	between	tumour	cells	and	non-
neoplastic	 stromal	 cells.	 The	 ability	 of	 a	 circulating	 tumour	 cell	 to	 escape	 the	 vasculature	 and	
extravasate	 into	 the	parenchyma	of	distant	 sites	 is	one	of	 the	 rate-limiting	 steps	of	 the	metastatic	
cascade33.	 This	 step	 requires	 dynamic	 tumour-endothelium	 communication	 through	 the	 release	 of	
vascular	permeability	factors	to	breach	the	endothelial	barrier,	thereby	enabling	the	passage	of	the	
tumour	cell	across	the	endothelium.	The	 identification	of	such	tumour-derived	permeability	factors	
will	 provide	 new	 mechanistic	 insights	 into	 metastasis,	 thereby	 offering	 new	 therapeutic	
opportunities.	 To	 address	 these	 challenges,	 we	 assumed	 that	 highly	 metastatic	 melanoma	 cells	
release	 in	 their	 extracellular	milieu	 a	 spectrum	of	 proteins	 that	 should	differ	 quantitatively	 and/or	
qualitatively	 from	 poorly	 metastatic	 cells.	 We	 thus	 used	 mass	 spectrometry	 to	 identify	 novel	
extracellular	tumour	factors	acting	on	endothelial	permeability.		
Our	approach	revealed	in	CM	from	metastatic	melanoma	the	presence	of	biological	factors,	such	as	
CCL234,	TGF-ß35,	IL836,	and	matrix	metalloproteinases37,	which	were	previously	implicated	in	tumour-
mediated	 disruption	 of	 endothelium	 integrity.	 Notably,	 Angiopoietin-like	 4,	 a	matricellular	 protein	
endowing	 breast	 tumours	 with	 the	 capacity	 to	 disrupt	 lung	 capillaries	 and	 seed	 pulmonary	
metastases35,	 38,	was	 absent	 from	our	 proteomic	 analysis.	 In	 line	with	 this,	 Angiopoietin-like	 4	was	
reported	 to	 prevent	 metastasis	 of	 melanoma	 B16	 cells	 by	 inhibiting	 vascular	 permeability	 and	
tumour	cell	motility39.	
One	other	matricellular	protein	emerging	from	our	differential	screen	is	SPARC.	A	previous	proteomic	
analysis	 identified	 high	 levels	 of	 SPARC	 associated	 with	 metastatic	 melanoma	 secretomes40.	 Our	
comparative	proteomic	analysis	corroborates	this	report,	but	further	extends	the	notion	that	SPARC	
is	associated	with	melanoma	progression	by	showing	differential	 levels	of	secreted	SPARC	between	
untransformed	 melanocytes,	 poorly	 metastatic	 and	 highly	 metastatic	 melanoma	 cells	
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(Supplementary	 Fig.1).	 Early	 studies	 have	 shown	 a	 role	 for	 SPARC	 in	 vascular	 biology	 in	 non-
malignant	 settings21,	 41.	 However,	 its	 importance	 in	 regulation	 of	 tumour-initiated	 vascular	
endothelial	 permeability	 has	 remained	 poorly	 studied.	 Therefore,	 we	 tested	 the	 possibility	 that	
melanoma-derived	SPARC	represents	a	novel	permeability	factor	favouring	tumour	cell	extravasation	
during	 haematogenous	 metastasis.	 We	 showed	 that	 expression	 of	 SPARC	 is	 sufficient	 to	 endow	
melanoma	cells	with	 the	ability	 to	disrupt	 the	 integrity	of	 lung	 capillaries	 and	 extravasate	 into	 the	
pulmonary	 parenchyma,	 which	 has	 not	 been	 reported	 before.	 Strikingly,	 our	 results	 indicate	 that	
metastatic	melanoma	cells	exert	their	pathological	inhibitory	effects	on	endothelial	integrity	in	large	
part	through	SPARC	secretion.	Indeed,	in	the	absence	of	tumour	SPARC,	no	significant	compensatory	
mechanisms	 were	 observed	 in	 our	 different	 experimental	 settings	 modelling	 in	 vitro	 and	 in	 vivo	
endothelial	permeability	and	melanoma	cell	extravasation	during	lung	metastatic	dissemination.		
SPARC	 (also	 known	 as	 osteonectin)	 is	 a	 multifunctional	 adapter	 protein	 operating	 both	 in	
physiological	processes	such	as	development	and	tissue	remodelling,	and	pathological	conditions	like	
cancer.	 SPARC	 regulates	 cell-cell	 and	 cell-matrix	 interactions	 in	 cell	 type	 and	 context	 dependent	
manner.	 In	 the	 tumour	 microenvironment,	 both	 neoplastic	 and	 neighbouring	 stromal	 cells	 can	
produce	SPARC,	thereby	imparting	a	complexity	of	action	for	SPARC	in	cancer.	In	melanoma,	we	and	
others	have	previously	 identified	an	autocrine	 role	 for	SPARC	 in	 regulating	 invasiveness,	epithelial-
mesenchymal-like	 transition,	 and	 melanoma	 survival14-16,	 42.	 Although	 SPARC	 expression	 has	 been	
clearly	 linked	 to	 cancer	 progression	 through	 cell-autonomous	 and	 non-autonomous	 actions	 in	 cell	
invasion	 and	 survival20,	 43,	 44,	 its	 function	 as	 a	 paracrine	 factor	 has	 remained	 poorly	 characterized.	
Paracrine	 functions	 attributed	 so	 far	 to	 SPARC	 in	 melanoma	 were	 related	 to	 inhibition	 of	
polymorphonuclear	leukocyte	recruitment43,	and	inhibition	of	proliferation	and	migration	capacities	
of	endothelial	cells	in	vitro45.	Supported	by	previous	evidence	that	elevated	SPARC	is	associated	with	
the	 occurrence	 of	 distant	 metastases	 and	 poor	 survival	 in	 melanoma	 patients30,	 31,	 our	 findings	
functionally	 demonstrate	 that	 SPARC	 mediates	 critical	 tumour	 cell-endothelium	 communications	
through	 a	 novel	 paracrine	 function	 on	 lung	 capillaries	 culminating	 in	 breaching	 vascular	 integrity	
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during	 metastatic	 dissemination.	 Clinically,	 our	 findings	 are	 underlined	 by	 the	 high	 expression	 of	
SPARC	 that	 we	 observed	 in	 pulmonary	 metastases	 of	 melanoma	 biopsies.	 Interestingly,	 a	 recent	
study	found	SPARC	overexpressed	mainly	in	lung	metastases	from	melanoma	as	compared	to	other	
primary	tumours46.		
Although	 endothelial	 cells	 in	 the	 tumour	 microenvironment	 are	 known	 to	 produce	 high	 levels	 of	
SPARC,	we	 found	 that	 endothelial-derived	 SPARC	 did	 not	 influence	melanoma	 cell	 transmigration,	
further	supporting	the	notion	that	tumour	and	host-derived	SPARC	have	different	biological	activities	
and	that	the	origin	of	SPARC	participates	to	the	complexity	of	SPARC	in	metastasis44,	47.	
The	question	remains	whether	secreted	SPARC	has	the	ability	to	exert	a	similar	task	on	endothelial	
permeability	in	other	virulent	cancers.	Our	findings	indicate	that	this	is	indeed	the	case	for	malignant	
glioma,	a	tumour	that	like	melanoma	has	a	neuroectodermal	origin.	Also,	the	observation	that	SPARC	
belongs	to	a	gene	signature	bestowing	 lung	metastasis	virulence	to	breast	cancer48	 further	adds	to	
the	paracrine	 influence	of	 tumour	SPARC	 in	 the	metastatic	disease.	However,	 in	contrast	 to	breast	
cancer	in	which	SPARC	has	no	role	in	primary	tumour	growth,	in	melanoma,	SPARC	provides	survival	
advantages	in	the	primary	tumour14,	16	as	well	as	metastatic	competence.			
Recruitment	 of	 various	 circulating	 blood	 cells	 such	 as	 macrophages,	 neutrophils	 or	 platelets	 by	
tumour-derived	factors	has	been	recognized	to	assist	tumour	cell	extravasation	at	metastatic	sites8,	
49.	 In	 this	 regard,	CCL2	 that	we	 identified	 in	our	proteomic	analysis,	was	 recently	 shown	 to	attract	
myeloid-derived	 monocytes	 and	 to	 promote	 efficient	 colon	 cancer	 cell	 extravasation34.	 Whether	
metastasizing	melanoma	cells	rely	on	SPARC	for	cooperative	interactions	with	circulating	blood	cells	
enabling	efficient	extravasation	across	the	vascular	barrier	remains	to	be	determined.		
Mechanistically,	 we	 demonstrate	 that	 SPARC	 activates	 VCAM1	 on	 endothelial	 cells,	 thereby	
disrupting	 intercellular	 junctions	 to	 enable	 the	 transmigration	 of	 melanoma	 cells	 and	 efficient	
extravasation	into	the	lung	parenchyma.	VCAM1	is	a	transmembrane	endothelial	glycoprotein,	which	
plays	a	critical	role	during	inflammatory	reaction	by	permitting	the	recruitment	of	leukocytes	at	the	
inflammatory	 sites.	 It	 contributes	 to	 the	 rolling	 and	 adhesion	 of	 leukocytes	 during	 the	 process	 of	
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leukocyte	diapedesis	via	high	affinity	binding	to	its	counter	receptor	α4ß1	expressed	at	the	leukocyte	
cell	 surface27,	 28.	 Another	 contributor	 to	 VCAM1-mediated	 leukocyte	 diapedesis	 was	 identified	 as	
being	 SPARC25.	 In	 addition,	 our	 data	 establish	 that	 SPARC	 contributes	 to	 the	 function	 of	 VCAM1	
during	melanoma	cell	 extravasation.	 Importantly,	neither	 knockdown	nor	overexpression	of	 SPARC	
affected	the	adhesion	of	melanoma	cells	in	vitro,	indicating	that	SPARC	is	dispensable	for	tumour	cell	
adhesion	to	the	endothelial	monolayer,	a	process	relying	on	α4ß1/VCAM1	interaction50.	Instead,	we	
show	that	 interaction	between	SPARC	and	VCAM1	activates	signalling	pathways	driving	endothelial	
paracellular	permeability,	a	key	process	facilitating	tumour	cell	diapedesis.	Our	present	results	reveal	
an	unprecedented	role	for	paracrine	stimulation	of	endothelial	cells	by	tumour-secreted	SPARC	and	
the	contribution	of	VCAM1	in	this	process.		
The	 signalling	 processes	 that	 control	 opening	 of	 the	 endothelial	 barrier	 and	 vascular	 integrity	 are	
highly	 complex.	 Physiological	 and	pathological	 pathways	 that	 increase	endothelial	 permeability	 act	
through	disruption	of	 intercellular	 junctions	 and	acto-myosin	 contractibility8.	A	 survey	of	 signalling	
pathways	activated	by	SPARC-competent	melanoma	CM	on	endothelial	cells	identified	the	p38	MAPK	
pathway	 as	 responsible	 for	 tumour-induced	 actin	 cytoskeleton	 remodelling	 and	 intercellular	 pores	
formation.	Activation	of	p38	MAPK	signalling	route	in	endothelial	cells	by	extravasating	tumour	cells	
has	 been	 observed	 previously	 in	 colon	 carcinoma	 cells34.	 In	 our	 study,	 SPARC-mediated	 VCAM1	
activation	 was	 found	 to	 stimulate	 SRC	 tyrosine	 kinase	 activity	 and	 p38-dependent	 MLC2	
phosphorylation.	The	effect	of	SPARC-competent	melanoma	CM	on	SRC	activation	is	consistent	with	
an	 earlier	 study	 showing	 that	 purified	 SPARC	 affects	 endothelial	 junction	 through	 a	 tyrosine	
phosphorylation-dependent	signalling	pathway51.	Phosphorylation	of	MLC2	 leads	to	 increased	acto-
myosin	 crossbridging,	 force	 development	 and	 subsequent	 contraction	 in	 endothelial	 cells.	 The	
ensuing	 cell	 retraction	 promotes	 gap	 formation	 and	 vascular	 permeability52.	 Previous	 studies	 have	
shown	that	antibody-mediated	crosslinking	of	VCAM1	stimulated	a	Rac/ROS/p38	signalling	cascade	
in	 endothelial	 cell	 during	 leukocyte	 transmigration29.	 Accordingly,	 we	 found	 that	 intracellular	 ROS	
production	 contributes	 to	 activation	 of	 p38	 MAPK	 and	 MLC2	 in	 endothelial	 cells	 stimulated	 by	
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SPARC-competent	melanoma	secretome.	We	can	thus	propose	that	activation	of	VCAM1	by	tumour-
derived	SPARC	uses	a	similar	molecular	 route	to	open	endothelial	barrier	and	facilitates	melanoma	
cell	 transmigration.	 In	 addition,	 the	 disruption	 of	 adherens	 junctions	 following	 VE-cadherin	
disassembly	 has	 also	 been	 reported	 to	 rely	 on	 p38	 MAPK	 signalling	 pathway 53,	 pointing	 to	 the	
central	role	of	this	pathway	in	tumour-induced	vascular	permeability.		
In	 conclusion,	 we	 discovered	 a	 new	 mechanism	 by	 which	 circulating	 melanoma	 cells	 can	 escape	
vasculature	 locations	 to	 establish	 metastases.	 Our	 findings	 demonstrate	 that	 SPARC	 functions	
through	 endothelial	 VCAM1	 as	 a	 major	 tumour	 permeability	 factor	 produced	 by	 metastatic	
melanoma	cells.	SPARC	has	the	ability	to	disrupt	the	integrity	of	vascular	endothelial	cell	layers	both	
in	 vitro	 and	 in	 the	 lungs,	 facilitating	 the	 passage	 of	 melanoma	 cells	 and	 their	 colonization.	
Importantly,	 our	 data	 offer	 a	 biochemical	 explanation	 for	 the	 long	 known	 clinical	 association	 of	
SPARC	expression	with	distant	metastasis	and	poor	outcome	in	melanoma	patients.	Tumour-secreted	
SPARC	 thus	 emerges	 as	 a	 multifunctional	 mediator	 of	 metastatic	 development	 contributing	 to	
tumour	cell	dissemination	at	the	primary	site	and	extravasation	at	distant	sites.	Our	study	provides	a	
rationale	and	mechanistic	basis	for	targeting	SPARC-VCAM1	interaction	and	their	downstream	target	
p38	MAPK	to	treat	the	metastatic	disease.		
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Methods	
Cells	 and	 reagents.	Human	 A375,	 1205Lu	 and	 SKMel28	 melanoma	 cell	 lines	 were	 obtained	 from	
ATCC.	 Human	 501Mel	 cells,	 kindly	 supplied	 by	 Ruth	 Halaban	 were	 described	 elsewhere42.	 Human	
WM9	 and	 WM793	 cell	 lines	 were	 the	 kind	 gift	 of	 Meenhard	 Herlyn	 and	 have	 been	 previously	
described42.	 Patient	 melanoma	 cells	 (Pt1,	 Pt2	 and	 Pt3)	 were	 the	 kind	 gift	 of	 Robert	 Ballotti	 and	
prepared	 as	 previously	 described54.	 Melanoma	 cells	 were	 cultured	 in	 Dulbecco’s	 modified	 Eagle	
Medium	 (DMEM)	 plus	 7	 %	 FBS	 (HyClone).	 Human	 U87	 glioma	 cells,	 generously	 provided	 by	
Dominique	 Figarella-Branger	 and	 Ellen	 Van	 Obberghen-Schilling	 were	 maintained	 in	 DMEM	
supplemented	 with	 7	 %	 FBS.	 Human	 primary	 epidermal	 melanocytes	 are	 from	 our	 lab	 stock	 and	
maintained	 as	 described	 previously15.	 501Mel	 cells	 expressing	 a	 myc-tagged	 SPARC	 (501Mel	
cl.SPARC)	 or	 carrying	 an	 empty	 expression	 cassette	 of	 pcDNA3	 vector	 (501Mel	 cl.CTRL)	 have	 been	
described16.	 For	 in	 vivo	 bioluminescence	 imaging,	 1205Lu	 LUC+,	 501Mel	 cl.CTRL	 LUC+	 and	 501Mel	
cl.SPARC	LUC+	cells	were	obtained	by	lentiviral	transduction	(pLenti6/V5-D-TOPO;	Life	Technologies)	
and	blasticidin	selection	(2	μg/ml).	HUVECs	and	HPMECs	were	obtained	from	Lonza	and	PromoCell,	
respectively.	Endothelial	cells	were	cultured	in	complete	EGM2	BulletKit	medium	supplemented	with	
2	%	FBS	 (HUVECs)	or	5	%	FBS	 (HPMECs)	and	 full	 supplements	 (Lonza)	and	were	used	between	2-6	
passages.	
Culture	reagents	were	purchased	from	Life	Technologies.	The	selective	inhibitor	of	p38	MAP	kinase	
SB202190	 was	 from	 Tocris	 Bioscience.	 An	 equal	 amount	 of	 DMSO	 was	 used	 as	 vehicle	 control.	
CellTracker	 CMFDA	 and	 CMTMR	 dyes	 (Molecular	 Probes),	 and	 FITC-Dextran	 (70,000	 MW)	 were	
purchased	 from	Life	Technologies.	Recombinant	human	SPARC	purified	 from	mouse	myeloma	cells	
was	purchased	from	R&D	System.	All	other	reagents	were	obtained	from	Sigma-Aldrich	unless	stated	
otherwise.	
	
Preparation	 of	 conditioned	medium.	Melanoma	 cells	were	 grown	 to	∼80	%	 confluence	 in	 growth	
culture	medium.	Following	washes	in	EGM2	medium	(Lonza),	cells	were	incubated	for	24	h	in	defined	
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endothelial	cell	medium	EGM2	with	full	supplements	and	2	%	FBS	(BulletKit,	Lonza)	at	37°C.	Medium	
conditioned	by	melanoma	cells	was	then	harvested,	centrifuged	at	3,500	rpm	for	5	min	and	filtrated	
by	0.22-µm	filters	to	eliminate	cell	debris.	The	preparation	of	CM	for	mass	spectrometry	analysis	 is	
described	 in	 Supplementary	 methods.	 In	 some	 experiments,	 extracellular	 vesicle-depleted	 culture	
supernatants	were	prepared	by	differential	ultracentrifugation	as	described55.	To	specifically	deplete	
SPARC	 from	 melanoma	 CM,	 we	 performed	 immunoprecipitation	 experiments.	 Briefly,	 CM	 from	
1205Lu	cells	was	incubated	overnight	with	15	µg	of	polyclonal	anti-hSPARC	antibody	(R&D	System)	or	
control	IgG	(Dako)	preabsorbed	to	protein	G-agarose	at	4°C.	The	cleared	CM	was	collected	and	added	
to	endothelial	cell	monolayer	for	in	vitro	permeability	assays.		
	
In	 vitro	 vascular	 permeability	 assay.	 1×105	 HUVECs	 or	 HPMECs	 were	 seeded	 onto	 gelatin-coated	
Transwell	 inserts	 (8	 µm	 pore	 size,	 Corning),	 and	 allowed	 to	 grow	 in	 complete	 EGM-2	 endothelial	
medium	to	confluence	for	4	days.	Endothelial	cell	monolayers	were	subsequently	stimulated	for	16	h	
with	TNFα	(10	ng/ml;	PeproTech).	CM	from	various	melanoma	cells	or	EGM2	medium	alone	(EGM2	
BulletKit,	2	%	FBS)	mixed	with	FITC-Dextran	70,000	MW	(0.05	mg/ml)	was	then	added	to	the	upper	
chamber	 of	 the	 Transwell.	 Permeability	was	monitored	by	 the	 endothelial	 transcellular	 passage	 of	
FITC-Dextran	 7	 h	 later	 on	 a	 Fluoroskan	 microplate	 reader.	 For	 neutralizing	 VCAM1	 antibody	
experiments	 TNFα–activated	 endothelial	 cell	 monolayer	 were	 pretreated	 for	 1	 h	 with	 anti-human	
VCAM1	blocking	antibody	(R&D	System)	or	IgG	isotype	control	(25	µg/ml	each).	
	
RNAi	studies	and	viral	transductions.	Negative	control,	SPARC,	VCAM1	and	p53	Stealth	RNAi	siRNA	
duplexes	were	designed	by	Invitrogen	(Life	Technologies).	Please	see	Supplementary	Table	2	for	the	
corresponding	 siRNA	 sequences.	 Transfection	 of	 siRNA	 was	 carried	 out	 using	 Lipofectamine	
RNAiMAX	(Life	Technologies),	at	a	final	concentration	of	50	nM.	Unless	stated	otherwise,	cells	were	
assayed	 3	 days	 post-transfection.	 A375	 cells	 stably	 expressing	 doxycycline-inducible	 SPARC	 short	
hairpin	 RNA	 (shRNA)	 were	 described	 previously16.	 Adenoviruses	 carrying	 an	 empty	 expression	
22  
cassette	 of	 pcDNA3	 vector,	 used	 as	 control	 (AdCTRL)	 or	 expressing	 SPARC	 (AdSPARC)	 or	 a	 SPARC	
truncation	mutant	 (SPARCΔEC)	with	a	myc-tag	at	 their	carboxyl	 terminus	have	also	been	described	
previously15.		
	
Cell	 lysis,	 immunoblot	 analysis	 and	 antibodies.	 Melanoma	 Cells	 were	 harvested	 as	 described	
before16.	 Endothelial	 cells	were	 lysed	 in	 RIPA	 buffer	 (50	mM	Tris-HCl	 (pH	 7.4);	 150	mM	NaCl;	 1	%	
NP40;	 0.1	 %	 SDS;	 0.5	 %	 Deoxycholate)	 supplemented	 with	 protease	 inhibitors	 and	 phosphatase	
inhibitors	(Roche	Diagnostics)	and	briefly	sonicated.	Whole	cell	 lysates	were	subjected	to	SDS-PAGE	
and	immunoblot	analysis.	The	following	antibodies	were	used	at	working	dilution	of	1:1,000,	unless	
otherwise	 mentioned:	 anti-SPARC	 (Haematologic	 Technologies),	 anti-HSP90	 (Santa	 Cruz	
Biotechnology),	 anti-VCAM1	 (Santa	 Cruz	 Biotechnology,	 dilution	 1:200),	 anti-Fibronectin	 (Sigma),	
anti-VE-cadherin	 (Zymed,	 dilution	 1:250),	 anti-p38,	 anti-phospho-p38	 (Thr180/Tyr182),	 anti-MLC2,	
anti-phospho-MLC2	 (Ser19)	 (dilution	 1:500),	 anti-ATF2	 (dilution	 1:500),	 anti-phospho-ATF2	
(Thr69/71)	(dilution	1:500),	anti-MKK3/6,	anti-phosho-MKK3	(Ser189)/MKK6	(Ser207),	anti-SRC,	anti-
phospho-SRC	 (Tyr416),	 anti-FAK,	 anti-phospho-FAK	 (Tyr397),	 anti-phospho-AKT	 (Ser473),	 anti-
phospho-SAPK/JNK	 (Thr183/Tyr185)	 and	 anti-phospho-ERK1/2	 (Thr202/Tyr204)	 were	 from	 Cell	
Signaling	 Technology.	 Peroxidase-conjugated	 anti-mouse	 and	 anti-rabbit	 antibodies	were	 from	Cell	
Signaling	 Technology.	 Peroxidase-conjugated	 anti-goat	 antibody	 was	 from	 Dako.	 Secondary	
antibodies	were	used	at	1:3,000	dilution.	Proteins	were	detected	by	enhanced	chemiluminescence	
(ECL)	Amersham	Western	Blotting	Detection	Reagents	(GE	healthcare	Life	Sciences).	Original	images	
of	blots	are	provided	in	Supplementary	Figs	11,	12	and	13.	
	
Fluorescence	and	confocal	microscopy.	Endothelial	cells	were	grown	to	confluence	on	gelatin	coated	
glass	coverslips.	After	the	indicated	treatments,	cell	monolayers	were	rinsed	briefly	in	PBS,	fixed	in	4	
%	formaldehyde	for	15	min,	and	incubated	with	primary	antibodies	against	Z01	(1:100;	Zymed)	or	ß-
catenin	(1:100;	BD	Biosciences)	overnight	at	4°C	in	humidified	chambers	in	a	solution	containing	0.2	
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%	 saponin	 and	 1	 %	 BSA.	 Cells	 were	 washed,	 incubated	 with	 Alexa	 Fluor-conjugated	 secondary	
antibodies	 (1:1000;	Molecular	 Probes)	 and	mounted	 in	 ProLong	 Gold	 Antifade	 Reagent	 with	 DAPI	
(Life	Technologies).	For	actin	staining,	fixed	cells	were	incubated	with	Texas	Red-X	phalloidin	(1:100;	
Molecular	 Probes)	 for	 1	 h	 at	 room	 temperature.	 Images	were	 captured	on	 a	 Zeiss	 LSM	510	META	
laser	scanning	confocal	microscope,	with	sequential	fluorophore	excitation.	
	
In	 vivo	 experiments.	All	mouse	 experiments	were	 carried	 out	 in	 accordance	with	 the	 Institutional	
Animal	 Care	 and	 the	 local	 ethics	 committee	 (CIEPAL-Azur	 agreement	 NCE/2014-179).	 Lung	
microvasculature	 permeability	 was	 determined	 by	 the	 FITC-Dextran	 extravasation	 technique	 as	
previously	 described35.	 Briefly,	 5-week-old	 female	 athymic	 (nu/nu)	mice	 (Harlan)	were	 i.v.	 injected	
with	1205Lu	cells	(1x106)	resuspended	in	100	µl	of	PBS.	24	h	post	inoculation,	mice	were	i.v.	injected	
with	FITC-Dextran	70,000	MW	at	1	mg	per	20	g	body	weight,	 followed	by	euthanasia	30	min	 later.	
Lungs	 were	 perfused	with	 PBS,	 dissected	 and	 homogenized	 for	 fluorescence	 quantification	 of	 the	
tracer	or	fixed	in	4	%	paraformaldehyde	and	frozen.	Cryosections	of	lungs	(8	µm)	were	stained	with	
an	 antibody	 against	 the	 vessel	 wall	marker	 α-SMA	 (1:100;	 Abcam)	 and	 examined	 by	 fluorescence	
microscopy	 for	 FITC-Dextran	 extravasation.	 Images	were	 acquired	 on	 a	 Zeiss	 LSM	 510	META	 laser	
scanning	confocal	microscope.	Lung	homogenates	were	prepared	in	RIPA	buffer	supplemented	with	
protease	inhibitors	and	phosphatase	inhibitors,	briefly	sonicated	and	quantified	using	a	protein	assay	
kit	 (Bio-Rad)	 according	 to	 the	 manufacturer’s	 manual.	 Fluorescence	 was	 measured	 in	 lung	
homogenates	 using	 a	 Fluoroskan	 microplate	 reader	 (excitation,	 485	 nm;	 emission,	 530	 nm).	
Quantification	 of	 extravasated	 FITC-dextran	 was	 determined	 in	 lung	 homogenates	 from	 different	
animals	 and	 calculated	 against	 a	 FITC-Dextran	 standard	 curve.	 Data	 are	 expressed	 as	 µg	 of	 FITC-
Dextran	per	µg	of	protein	from	lung	homogenates.		
For	short-term	lung	colonization	assays,	melanoma	cell	populations	were	differentially	labelled	with	
5	µM	CellTracker	Green	CMFDA	or	CellTracker	Orange	CMTMR	dyes	as	described56.	Equal	numbers	
(7.5x105)	were	coinjected	into	the	tail	veins	of	nude	mice,	which	were	sacrificed	30	min	or	24	h	later.	
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At	 24	 h,	 lungs	were	 flushed	 and	 perfused	 free	 of	 blood	with	 PBS	 to	 remove	 intravascular	 tumour	
cells.	Fluorescently	labelled	cells	in	lungs	were	counted	microscopically.	
For	experimental	 lung	metastasis	 studies,	1x106	melanoma	cells	engineered	 to	express	a	 luciferase	
reporter	gene	(LUC+	cells)	were	resuspended	in	100	µl	of	PBS	and	injected	into	the	tail	veins	of	nude	
mice.	Lung	metastasis	was	monitored	and	quantified	using	bioluminescence	imaging	(BLI).	Mice	were	
anesthetized	 and	 injected	 intraperitoneally	with	 50	mg/kg	D-luciferin	 (PerkinElmer)	 in	 PBS.	 Images	
were	acquired	using	a	Photon	 Imager	 (Biospace	 Lab)	 system	and	data	analysed	with	 the	M3Vision	
software	 (Biospace	 Lab).	 The	 total	 numbers	 of	 photons	 per	 second	 per	 steradian	 per	 square	
centimeter	 were	 recorded.	 For	 BLI	 plots,	 photon	 flux	 was	 calculated	 for	 each	 mouse	 by	 using	 a	
rectangular	region	of	interest	encompassing	the	thorax	of	the	mouse	in	a	prone	position.	This	value	
was	normalized	to	the	value	obtained	 immediately	after	 injection	(15	min),	so	that	all	mice	had	an	
arbitrary	starting	BLI	signal	of	100.	Mice	were	imaged	twice	a	week.	For	ex	vivo	BLI,	lungs	harvested	
and	 perfused	 with	 PBS	 were	 immersed	 in	 D-luciferin	 diluted	 in	 PBS	 to	 a	 final	 concentration	 of	 5	
mg/ml	for	5	min	before	imaging.			
For	 immunostaining	of	metastases,	 lungs	were	perfused	with	PBS,	 fixed	 in	 4	%	paraformaldehyde,	
OCT-embedded	 (Gentaur)	 and	 cryosectioned.	 Sections	 of	 lungs	 (8	 µm)	 were	 stained	 with	
Hematoxylin/Eosin	or	incubated	with	antibodies	against	myc	(1:100;	Cell	Signaling	Technologies)	and	
NKI/BETEB	(1:20;	Hycult	Biotech)	before	detection	with	Alexa	Fluor-conjugated	secondary	antibodies	
(1:1,000;	Molecular	 Probes).	 Sections	were	mounted	 in	 ProLong	Gold	 Antifade	 Reagent	with	 DAPI	
(Life	Technologies).	Images	were	acquired	on	a	Zeiss	(PALM)	microscope.	
In	the	study	with	VCAM1	blocking	antibody,	25	µg	of	anti-mouse	VCAM1	antibody	(eBioscience)	or	
IgG	 isotype	 control	 were	 administrated	 through	 tail	 vein	 injection	 30	 min	 prior	 1205Lu	 LUC+	
inoculation.	Lung	extravasation	at	24	h	was	monitored	and	quantified	by	bioluminescence	imaging	as	
described	above.	
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Transendothelial	 migration.	 1×105	 HUVECs	 or	 HPMECs	 were	 plated	 in	 the	 upper	 chamber	 of	 a	
gelatin-coated	 Transwell	 insert	 and	 grown	 in	 complete	 endothelial	 medium	 to	 confluence.	 The	
endothelial	monolayer	 was	 then	 left	 untreated	 or	 treated	with	 human	 TNFα	 (10	 ng/ml)	 for	 16	 h.	
Melanoma	 cells	 were	 pulsed	 with	 5	 µM	 CellTracker	 Green	 CMFDA	 dye	 for	 30	 min,	 detached	 by	
HyQTase	treatment	(HyClone)	and	plated	on	top	of	the	endothelial	monolayer.	Cells	were	allowed	to	
migrate	 for	 7-24	 h	 at	 37°C	 in	 5	 %	 CO2.	 Complete	 EGM2	 medium	 plus	 10	 %	 FBS	 was	 used	 as	 a	
chemoattractant.	The	Transwells	were	then	fixed	in	4	%	paraformaldehyde,	cells	on	the	apical	side	of	
each	insert	were	scraped	off,	and	the	Transwell	membrane	mounted	onto	glass	slides.	Migration	to	
the	 basolateral	 side	 of	 the	 membrane	 was	 visualized	 with	 a	 Zeiss	 (PALM)	 immunofluorescent	
microscope	at	x5	magnification.	Pictures	of	5	 random	fields	were	captured	 for	quantification	using	
NIH	 ImageJ	 analysis	 software.	All	 experiments	were	performed	 in	duplicates	 and	 repeated	at	 least	
three	times.		
	
Tumor-endothelial	cell	adhesion	assay.	The	adhesion	assays	were	performed	in	black	96-well	culture	
dishes	in	triplicate.	HUVECs	were	seeded	onto	gelatin,	allowed	to	grow	to	confluence	for	4	days	and	
stimulated	for	16	h	with	TNFα	(10	ng/ml).	Melanoma	cells	were	pulsed	with	5	µM	CellTracker	Green	
CMFDA	 for	 30	min	 and	 collected	 by	 HyQTase	 treatment.	 Fluorescent	 dye-labelled	 cells	were	 then	
allowed	to	adhere	onto	the	endothelial	cell	monolayer	for	7	h.	Non-adherent	cells	were	removed	by	
washing	with	PBS	supplemented	with	1	mM	CaCl2	and	1	mM	MgCl2	and	fluorescence	was	measured.	
Data	are	expressed	as	the	percentage	of	adherent	cells	per	total	cells.	
	
Detection	of	ROS	by	flow	cytometry.	ROS	levels	were	measured	using	the	redox-sensitive	dye	CM-
H2DCFDA	 (Molecular	 Probes,	 Life	 Technologies).	 The	 green	 fluorescence	 was	 collected	 using	 a	
Miltenyi	Biotec	flow	cytometer	and	the	MACSQuantify	software	for	acquisition	and	analysis.	
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Human	samples	and	immunohistochemistry.	Lung	metastatic	melanoma	specimens	were	obtained	
from	 the	 consenting	 patient	 through	 the	 Histopathology	 and	 Dermatology	 Departments,	 Nice	
University	Hospital,	France.	Formalin-fixed,	paraffin-embedded	tissue	blocks	were	retrieved	from	the	
archive	and	analysed	by	IHC.	The	SPARC	polyclonal	antibody	(1:100;	R&D	System)	was	incubated	with	
tissue	 sections	 (2	 μm)	 after	 heat-induced	 epitope	 retrieval	 (pH	 6.0).	 The	 samples	 were	 incubated	
with	primary	antibody,	 followed	by	 incubation	with	a	secondary	antibody	conjugated	to	peroxidase	
(1:100;	 Dako).	 Detection	 was	 performed	 using	 diaminobenzidine	 for	 8	 min,	 and	 the	 slides	 were	
counterstained	with	Hematoxylin.	
	
ELISA.	 The	 concentration	 of	 SPARC	 in	 various	 CM	 of	melanoma	 cell	 lines	 or	 serum	 samples	 were	
quantified	 using	 the	 human	 SPARC	Quantikine	 ELISA	 kit	 (R&D	 Systems)	 as	 per	 the	manufacturer’s	
protocol.	 After	 receiving	 their	 informed	 consent,	 we	 obtained	 sera	 from	 nine	 patients	 with	
metastatic	melanoma	 treated	at	 the	Department	of	Dermatology,	Nice	University	Hospital,	 France.	
Eight	healthy	volunteers	were	recruited	as	controls.	Results	from	two	independent	experiments	were	
normalized.	
	
Statistics.	 Unless	 otherwise	 stated	 all	 experiments	 were	 repeated	 at	 least	 three	 times	 and	
representative	data/images	are	shown.	Statistical	data	analysis	was	performed	using	GraphPad	Prism	
5	 software.	Unpaired	 two-tailed	Student’s	 t-test	and	Mann-Whitney’s	 test	were	used	 for	 statistical	
comparisons	between	2	groups	and	Kruskal-Wallis’s	test	with	Dunn’s	post-tests	or	two-way	ANOVA	
test	with	Bonferroni	post-tests	to	compare	3	or	more	groups.	Error	bars	are	±	s.e.m.		
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Figure	legends	
	
Figure	 1.	 Tumour-secreted	 SPARC	 reduces	 endothelial	 monolayer	 integrity.	 (a)	 Schematic	
representation	 of	 CM	 production	 from	melanoma	 cell	 cultures.	 After	 24	 h,	 CM	was	 collected	 and	
used	for	permeability	assays	or	mass	spectrometry	analysis	(see	Supplementary	Fig.	1	and	Table	1).	
(b)	Primary	endothelial	cells	(HUVECs)	were	seeded	into	gelatin-coated	Boyden	chambers,	allowed	to	
grow	to	confluence	and	then	treated	with	TNFα	(10	ng/ml)	overnight.	Permeability	was	determined	
by	a	FITC-Dextran	assay	7	h	after	addition	of	CM	from	melanoma	cells	depleted	or	not	for	SPARC	by	
siRNA	 or	 from	 501Mel	 cells	 stably	 overexpressing	 SPARC	 (cl.	 SPARC)	 or	 not	 (cl.	 CTRL).	 Bar	 graphs	
show	 mean	 ±	 s.e.m.,	 n=2	 independent	 experiments	 performed	 in	 triplicate.	 Upper	 panels	 show	
representative	anti-SPARC	blots.	Ponceau	staining	was	used	as	loading	control.	siCTRL,	control	siRNA;	
siSPARC,	SPARC	siRNA.	(c)	Permeability	analysis	of	human	pulmonary	microvascular	endothelial	cells	
(HPMECs)	 7	 h	 after	 addition	 of	 1205Lu	 CM	 depleted	 or	 not	 for	 SPARC.	 Bar	 graphs	 show	mean	 ±	
s.e.m.,	 n=2	 independent	 experiments	 performed	 in	 triplicate.	 (d)	 Permeability	 of	 HUVECs	 was	
assayed	 using	 1205Lu	 CM	 cleared	 from	 SPARC	 by	 immunoprecipitation	 (IP).	 Inset	 shows	
representative	SPARC	immunoblot	analysis	of	the	cleared	CM.	Bar	graphs	show	mean	±	s.e.m.,	n=2	
independent	 experiments	 performed	 in	 triplicate.	 (e)	 Permeability	 assay	was	 performed	 using	 CM	
from	1205Lu	cell	cultures	depleted	for	SPARC	by	siRNA	and	rescued	by	recombinant	human	SPARC	
(rhSPARC).	 Increasing	 doses	 of	 rhSPARC	were	 added	 in	 the	 upper	 chamber	 (2,	 5	 or	 10	µg/ml)	 and	
FITC-Dextran	fluorescence	was	determined	in	the	lower	chamber	7	h	after	addition	of	CM.	Bar	graphs	
show	 mean	 ±	 s.e.m.,	 n≥3	 independent	 experiments	 performed	 in	 triplicate.	 (f)	 Representative	
photomicrographs	 of	 HUVEC	 monolayers	 incubated	 for	 7	 h	 with	 CM	 from	 1205Lu	 cells	 depleted	
(siSPARC)	 or	 not	 (siCTRL)	 for	 SPARC,	 compared	 to	 control	 medium.	 Immunofluorescence	 for	 ZO1	
(green),	 F-actin	 (red)	 and	 nuclei	 (blue)	 show	 intercellular	 gaps	 between	 endothelial	 cells	 in	 the	
presence	 of	 siCTRL	 CM	 (asterisks).	 Bar,	 20	 µm.	 (g)	Quantification	 of	 intercellular	 gaps.	 Bar	 graphs	
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show	mean	±	s.e.m	(n=7	independent	fields).	P	values	shown	in	(b),	Unpaired	t-test,	(c-e,	g),	two-way	
ANOVA.	*P<0.05,	**P<0.01,	***P<0.001.	
	
Figure	 2.	 Tumour-derived	 SPARC	 contributes	 to	 lung	 vascular	 permeability.	 (a)	 Schematic	
representation	 of	 the	 FITC-Dextran	 lung	 extravasation	 assay	 procedure.	 Nude	mice	 were	 injected	
into	 the	 lateral	 tail	 vein	 with	 1205Lu	 or	 501Mel	 cells	 modified	 for	 SPARC	 expression.	 24	 h	 post	
inoculation,	mice	 received	 1	mg	 FITC-Dextran	 (70	 kDa)/20g	 bodyweight	 intravenously	 and	 animals	
were	 sacrificed	 30	 min	 later.	 Lungs	 were	 perfused	 free	 of	 blood with	 PBS	 and	 fixed	 for	 confocal	
microscopy	examination	or	homogenized	 for	 fluorescence	measurement.	 (b)	Representative	 image	
of	 lung	sections	showing	extravasated	FITC-Dextran	 (green)	after	1205Lu	cells	 inoculation.	Sections	
were	stained	with	antibodies	against	the	vessel	wall	marker	α-SMA	(red)	and	DAPI	(blue).	Asterisks	
show	 microvascular	 pulmonary	 lumen.	 Bar,	 20	 µm.	 (c)	 Representative	 images	 of	 lung	 sections	
following	 FITC-Dextran	 administration	 in	 the	 presence	 of	 1205Lu	 cells	 depleted	 (siSPARC)	 or	 not	
(siCTRL)	 for	 SPARC.	 Sections	 were	 stained	 with	 DAPI	 (blue)	 prior	 to	 confocal	 microscopy	 analysis.	
Arrows	show	typical	accumulation	of	FITC-Dextran	molecules	within	the	lung	parenchyma	of	1205Lu-
injected	mice.	Bar,	100	µm.	(d)	Quantification	of	lung	microvasculature	permeability	in	the	presence	
of	 1205Lu	 cells	 depleted	 (siSPARC)	 or	 not	 (siCTRL)	 for	 SPARC.	 Scatter	 plots	 of	 FITC-Dextran	
fluorescence	 in	 lungs	 are	 shown	 (Dot,	 single	 mouse,	 n=5	 mice	 per	 group).	 For	 each	 mouse,	
permeability	 was	 reported	 in	 micrograms	 of	 FITC-Dextran	 per	 micrograms	 of	 protein	 from	 lung	
homogenates.	 (e)	 Quantification	 of	 lung	microvasculature	 permeability	 in	 the	 presence	 of	 501Mel	
cells	stably	overexpressing	SPARC	(MelSPARC)	or	not	(MelCTRL)	determined	as	above	(n=5	mice	per	
group).	P	values	shown	in	(d),	two-way	ANOVA,	(e),	Kruskal-Wallis’s	test.	*P<0.05,	**P<0.01.	ns,	not	
significant.		
	
Figure	 3.	 Tumour-derived	 SPARC	 promotes	 melanoma	 cell	 extravasation.	 (a)	 HUVECs	 grown	 to	
confluence	on	transwell	inserts	were	activated	or	not	(control)	with	TNFα	(10	ng/ml).	CMFDA-stained	
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melanoma	cell	 lines	(1205Lu,	A375)	or	short-term	cultured	melanoma	cells	 (Pt1	to	Pt3)	transfected	
with	control	or	SPARC	siRNA	were	seeded	onto	the	inserts.	After	7	h,	melanoma	cell	migration	across	
HUVECs	 monolayers	 was	 analysed.	 Bar	 graphs	 show	 mean	 ±	 s.e.m.	 (n=10	 random	 fields	 from	 a	
duplicate	determination).	Results	are	representative	of	at	 least	three	 independent	experiments.	 (b)	
Analysis	 of	migration	of	 1205Lu	 cells	 depleted	 (siSPARC)	 or	 not	 (siCTRL)	 for	 SPARC	across	HPMECs	
monolayers.	 Bar	 graphs	 show	 mean	 ±	 s.e.m.	 Results	 are	 representative	 of	 two	 independent	
experiments.	 (c)	 Analysis	 of	 migration	 of	 control	 (cl.CTRL)	 or	 SPARC	 overexpressing	 (cl.SPARC)	
501Mel	cells	across	HUVECs	monolayers.	Bar	graphs	show	mean	±	s.e.m.	Results	are	representative	
of	at	 least	three	 independent	experiments.	 (d)	Schematic	of	 the	short-term	lung	colonization	assay	
procedure.	Melanoma	cells	modified	or	not	for	SPARC	expression	were	labelled	with	CMTMR	(red)	or	
CMFDA	 (green)	 fluorescent	 dyes.	 Fluorescent	 cells	 were	 co-injected	 into	 tail	 veins	 of	 nude	 mice,	
which	were	sacrificed	30	min	or	24	h	later.	Lungs	were	collected	and	at	the	24	h	time	point	perfused	
free	of	blood	with	PBS	to	remove	intravascular	tumour	cells.	Fluorescently	labelled	cells	in	lungs	were	
counted	microscopically.	 (e)	Quantification	of	 lung	 colonization	by	1205Lu	 cells	 depleted	 (siSPARC,	
green)	or	not	(siCTRL,	red)	for	SPARC.	The	relative	proportion	of	each	cell	population	present	within	
the	lungs	at	the	indicated	times	post	injection	was	determined.	Bar	graphs	show	mean	±	s.e.m.	(n=5	
randomly	 chosen	 fields).	 Results	 are	 representative	 of	 two	 independent	 experiments.	 (f)	
Quantification	 of	 lung	 colonization	 by	 control	 (cl.CTRL,	 green)	 or	 SPARC	 overexpressing	 (cl.SPARC,	
red)	 501Mel	 cells.	 The	 relative	 proportion	 of	 each	 cell	 population	 present	within	 the	 lungs	 at	 the	
indicated	 times	post	 i.v.	 injection	was	determined.	 Bar	 graphs	 show	mean	±	 s.e.m.	 (n=5	 randomly	
chosen	fields).	Representative	images	of	lungs	at	30	min	and	24	h	are	shown.	Bar,	100	µm.	P	values	
shown	in	(a-c),	Unpaired	t-test,	(e,f),	Mann-Whitney’s	test.	**P<0.01,	***P<0.005.		
	
Figure	4.		Tumour-derived	SPARC	is	required	for	melanoma	lung	metastasis.	(a)	Control	and	SPARC-
depleted	 1205Lu	 LUC+	 cells	 were	 i.v.	 injected	 into	 nude	 mice	 (n=6	 mice	 per	 group)	 and	 lung	
metastasis	was	monitored	and	quantified	using	a	photon	 imager.	Representative	 images	of	photon	
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fluxes	produced	by	bioluminescent	cancer	cells	from	day	0	to	day	18	are	shown	(3	mice	per	group	are	
shown).	Results	 are	 representative	of	 three	 independent	experiments.	 (b)	Ex	vivo	 analysis	of	 lungs	
from	1205Lu	LUC+	siCTRL	or	siSPARC	injected	mice.	Scatter	plots	of	 lung	metastatic	foci	(left	panel,	
**P=0.0079,	 Mann-Whitney’s	 test)	 and	 normalized	 photon	 flux	 (right	 panel,	 **P=0.0024,	 Mann-
Whitney’s	 test).	Dot,	 single	mouse,	n=6.	Representative	ex	 vivo	 BLI	 imaging	of	 lung	mets	 is	 shown	
(bottom).	(c)	Mice	were	injected	with	501Mel	LUC+	overexpressing	(cl.SPARC)	or	not	(cl.CTRL)	myc-
tagged	SPARC	(n=5	mice	per	group).	After	80	days,	mice	were	sacrificed	and	ex	vivo	analysis	of	lungs	
was	performed.	Scatter	plots	of	lung	metastatic	foci	(left	panel,	*P=0.045,	Mann-Whitney’s	test)	and	
normalized	 photon	 flux	 (right	 panel,	 *P=0.045,	Mann-Whitney’s	 test).	 Dot,	 single	mouse,	 n=5.	 (d)	
Histological	(H&E)	and	immunofluorescence	(IF)	analyses	of	lung	sections	from	mouse	injected	with	
501Mel	 control	 or	 501Mel	 overexpressing	myc-tagged	 SPARC	 after	 80	 days.	 Upper	 panels	 show	 a	
representative	H&E	staining	of	lung	sections.	Lower	panels	show	confocal	microscopy	images	of	lung	
sections	 labelled	 with	 DAPI	 (blue),	 antibodies	 against	 Myc	 tag	 (red)	 and	 the	 melanocytic	 marker	
NKI/BETED	(green).	Bar,	500	µm.		(e)	Depletion	of	SPARC	impairs	lung	colonization	by	melanoma	cells	
independently	of	p53	activation.	1205Lu	LUC+	cells	silenced	for	SPARC	(siSPARC),	p53	(sip53)	or	both	
were	injected	into	nude	mice	and	lung	metastasis	in	each	group	was	monitored	until	day	18.	Scatter	
plots	of	lung	metastatic	foci	are	shown	(**P<0.01,	***P<0.001,	two-way	ANOVA.	ns,	not	significant).	
Dot,	single	mouse,	n=6.		
	
Figure	5.	Endothelial	VCAM1	mediates	SPARC-induced	vascular	permeability	and	extravasation.	(a)	
Control	 IgG	or	VCAM1	blocking	antibodies	 (25	µg/ml)	were	added	to	HUVECs	monolayers	1	h	prior	
addition	of	 the	 indicated	melanoma	cells.	 In	 vitro	 transendothelial	migrations	were	quantified.	Bar	
graphs	 show	 mean	 ±	 s.e.m.,	 n=2	 independent	 experiments	 performed	 in	 triplicate.	 (b)	 Activated	
HUVECs	 monolayers	 were	 treated	 with	 IgG	 or	 VCAM1	 blocking	 antibodies	 and	 FITC-Dextran	
permeability	assays	were	performed	using	1205Lu	CM.	Bar	graphs	show	mean	±	s.e.m	of	 triplicate	
determinations.	 (c)	HUVECs	transfected	with	siCTRL	or	siRNA	against	VCAM1	were	activated	or	not	
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with	TNFα.	Transmigration	assays	were	performed	with	1205Lu	cells.	Bar	graphs	show	mean	±	s.e.m.	
Results	 are	 representative	 of	 three	 independent	 experiments.	 Inset	 shows	 immunoblot	 analysis	 of	
VCAM1	 suppression	 in	 HUVECs.	 (d)	 Representative	 confocal	 microscopy	 of	 HUVECs	 monolayers	
depleted	or	not	for	VCAM1	incubated	7	h	with	1205Lu	CM.	Immunofluorescence	for	ZO1	(green),	F-
actin	 (red)	and	nuclei	 (blue)	 show	 intercellular	gap	 into	 the	vascular	monolayer	expressing	VCAM1	
(asterisks).	 Bar,	 10	 µm.	 (e)	Mice	were	 administrated	with	 25	 µg	 of	 VCAM1	 blocking	 antibodies	 or	
control	 IgG	30	min	prior	 to	 inoculation	of	1205Lu	 LUC+	 cells.	 Lung	 colonization	by	melanoma	cells	
was	 analysed	 after	 24	 h.	 Scatter	 plots	 of	 normalized	photon	 flux	 in	 lungs.	Dot,	 single	mouse,	n=6.	
Representative	 images	 of	 photon	 fluxes	 produced	 by	 bioluminescent	 cells	 are	 shown.	 (f)	 The	 left	
inset	 shows	 the	 functional	 domains	 of	 SPARC	 and	 of	 the	 ∆EC	 mutant.	 AC,	 acidic	 domain;	 FS,	
follistatin-like	 domain	 and	 EC,	 extracellular	 Ca2+	 binding	 domain.	 501Mel	 cells	were	 infected	with	
control	 adenovirus	 (AdCTRL),	 adenovirus	encoding	myc-tagged	SPARC	 (AdSPARC)	or	 SPARC	mutant	
deleted	of	 the	VCAM1	binding	 domain	 (Ad	 SPARC∆EC).	 Cell	migrations	 across	HUVECs	monolayers	
were	 realized	 and	 FITC-Dextran	 permeability	 assays	were	 performed	 using	 CM	 from	 the	 indicated	
transduced	501Mel	cells.	Bar	graphs	show	mean	±	s.e.m.,	n=2	independent	experiments	performed	
in	 triplicate.	 Expression	 levels	 of	 endogenous	 SPARC	 and	 myc-tagged	 SPARC	 transgenes	 were	
analysed	by	 immunoblot	 (right	 inset).	 (g)	Activated	HUVECs	monolayers	 transfected	with	 siCTRL	or	
siVCAM1	were	 incubated	 with	 5	 µg/ml	 of	 rhSPARC	 for	 7	 h.	 Endothelial	 permeability	 was	 assayed	
using	FITC-Dextran.	Bar	graphs	show	mean	±	s.e.m.	of	 triplicate	determinations.	P	 values	shown	 in	
(a,c,f	 (left)),	 Unpaired	 t-test,	 (b,f,(right),g),	 two-way	 ANOVA,	 (e)	 Mann-Whitney’s	 test.	 *P<0.05,	
**P<0.01,	***P<0.005.		
	
Figure	6.	 	 SPARC-VCAM1	 induced	endothelial	barrier	dysfunction	 is	driven	by	a	p38	MAPK/MLC2	
pathway.	(a)	Immunoblot	analysis	of	HUVECs	monolayers	activated	or	not	with	TNFα	and	incubated	
for	7	h	with	CM	 from	1205Lu	cells	depleted	or	not	 for	 SPARC.	 (b)	 Immunoblot	analysis	of	HUVECs	
monolayers	untreated	or	 treated	with	p38	kinase	 inhibitor	SB202190	 (10	µM)	1	h	prior	 incubation	
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with	1205Lu	cell	CM	compared	to	medium.	(c)	HUVECs	treated	or	not	with	p38	 inhibitor	SB202190	
were	 incubated	 with	 CM	 from	 1205Lu	 cells	 or	 with	 medium	 alone.	 Endothelial	 monolayers	 were	
imaged	by	confocal	microscopy	following	immunofluorescence	staining	of	ZO1	(green),	F-actin	(red)	
and	nuclei	(blue).	Intercellular	gaps	induced	by	melanoma	CM	into	the	vascular	monolayer	(asterisks)	
were	absent	 in	 SB202190-treated	monolayers.	 Scale	bar,	 10	µm.	 (d)	Quantification	of	migration	of	
1205Lu	 cells	 across	 resting	 and	 activated	 HUVECs	 monolayers	 treated	 or	 not	 with	 p38	 inhibitor	
SB202190	 (10	 µM)	 1	 h	 prior	 addition	 of	 melanoma	 cells.	 Bar	 graphs	 show	 mean	 ±	 s.e.m.	 (n=10	
random	 fields	 from	 a	 triplicate	 determination).	 (e)	 FITC-Dextran	 permeability	 assay	 of	 HUVECs	
monolayers	untreated	or	treated	with	p38	 inhibitor	SB202190	(10	µM)	1	h	prior	 incubation	for	7	h	
with	 control	 medium	 or	 CM	 from	 1205Lu	 cells.	 Bar	 graphs	 show	 mean	 ±	 s.e.m	 of	 triplicate	
determinations.	All	results	are	representative	of	at	three	independent	experiments.	P	values	shown	
in	(d),	Unpaired	t-test,	(e),	two-way	ANOVA.	**P<0.01.		
	
Figure	 7.	 	 SPARC	 is	 associated	 with	 distant	 metastasis	 in	 human	 melanoma.	 (a)	
Immunohistochemical	 staining	 for	 SPARC	 in	 lung	 melanoma	 metastases	 from	 patients	 (n=4).	
Photomicrographs	 of	 melanoma	 metastases	 at	 low-power	 magnification	 (a-c)	 and	 high-power	
magnification	 (d).	Arrowheads	point	 to	SPARC	positive	 tumour	cells	whereas	asterisks	 show	SPARC	
negative	non	tumoural	tissues.	Original	magnification	x200	for	panel	a,	x100	for	panels	b	and	c	and	
x1000	for	panel	d.	(b)	Serum	analysis	for	SPARC	from	metastatic	melanoma	(MM)	patients	compared	
to	healthy	donors	(n=8;	P=0.015,	Mann-Whitney’s	test).	(c)	Schematic	model	depicting	how	tumour-
derived	 SPARC	 triggers	 endothelial	 permeability.	 	 SPARC	 binding	 to	 VCAM1	 promotes	 actin	
remodelling	and	opening	of	endothelial	junctions	through	a	ROS-MEKK3/6-p38MAPK-MLC2	signalling	
pathway.		
	
	
	
	







